The Dual-Agonist Advantage: Comparing Tirzepatide (GIP/GLP-1) Efficacy Against Single GLP-1 RAs (Semaglutide) in T2DM
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This narrative review explores the therapeutic shift in Type 2 Diabetes Mellitus (T2DM) management from single-receptor agonists to dual-agonist therapies. While selective GLP-1 receptor agonists like semaglutide have served as a primary treatment standard for metabolic control, the emergence of tirzepatide a "Tw incretin" targeting both GIP and GLP-1 receptors-presents a new clinical advantage. By simultaneously activating these distinct metabolic pathways, tirzepatide achieves a synergistic effect that enhances insulin secretion and improves adipose tissue regulation beyond the capabilities of single-hormone agents. Clinical comparisons indicate that tirzepatide provides superior reductions in blood glucose and body weight, helping a greater proportion of patients achieve near-normal metabolic levels. Furthermore, the dual-agonist profile shows promising improvements in cardiovascular markers and lipid metabolism with a safety profile characterized primarily by transient gastrointestinal side effects. This paper synthesizes the mechanistic benefits of dual agonism and evaluates its potential to redefine the gold standard for intensive T2DM therapy.
Fields of Study & Subjects
Diabetes Treatment and Management
Diabetes Management and Research
Pharmacology and Obesity Treatment
Publication details
- Volume
- 1
- Issue
- 1
- Pages
- 1–11
- Publication date
- 1 January 2026
- Language
- EN